Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases across the country, testing that Second Circuit decision in other regions.

Sanofi brings Japan exec to U.S. to fill empty pharma chief's shoes

Sanofi has a new North American chief. The French drugmaker has slotted Jez Moulding into the slot Anne Whitaker suddenly vacated a few weeks ago. He'll head up the North American pharma business after serving as SVP of the company's Japan and Pacific operations.

Who's worried about the drug-pricing debate? Regeneron's CEO, for one

Are C-level execs really listening to the brouhaha over drug prices? With new drugs still rolling out in the U.S. at big premiums, one might think not. But if Regeneron chief Leonard Schleifer is speaking for his colleagues, then the answer is yes.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Want a window into the future of hepatitis C drug marketing? Keep an eye on Europe. Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

It's official: The Pfizer-AstraZeneca deal talk can resume

Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.

Looking for a Xalkori boost, Pfizer adds targeted med to Merck IO pact

Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.

Apotex fails to block FDA import ban with NAFTA; Iroko nabs osteoarthritis approval for Zorvolex;

@FiercePharma: Top-read on FierceAnimalHealth Monday: Merck releases tilapia vaccine. Article | Follow @FiercePharma @EricPFierce: Boehringer Ingelheim opens a $30M packaging plant for its Vetmedica...

Galena says goodbye to ex-CEO, no severance pay included

Galena Biopharma announced a new CEO last week. The outgoing chief, Mark Ahn, was said to be leaving to pursue "other long-held personal and professional goals." That's an obvious red flag: Ahn must have been not-so-gently reminded that he had other long-held goals.

Celebrity pitch-folks may not be worth the money, study finds

Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods?

Mad at NICE's cancer drug rejections? Look to drugmakers, agency chief says

Political shilly-shallying about the cost of drugs has to end, the chief of the U.K.'s cost-effectiveness agency says. Government officials and politicians need to be up front with the public about one stark fact: The country's health service just can't afford every drug that can help patients.